These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34119678)

  • 21. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
    Mossong J; Putz L; Schneider F
    Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
    Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
    An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C; Pachón I; de Ory F
    Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
    Johnson H; Hillary IB; McQuoid G; Gilmer BA
    Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.
    Plans P; de Ory F; Campins M; Álvarez E; Payà T; Guisasola E; Compte C; Vellbé K; Sánchez C; Lozano MJ; Aran I; Bonmatí A; Carreras R; Jané M; Cabero L
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1161-71. PubMed ID: 25666082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevalence of maternal measles, rubella, mumps and varicella antibodies in the first six months of life].
    Devecioğlu E; Gökçay G; Boran P; Eren T; Yılmaz G; Badur S
    Mikrobiyol Bul; 2018 Jul; 52(3):324-327. PubMed ID: 30156519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.
    Nogareda F; Gunregjav N; Sarankhuu A; Munkhbat E; Ichinnorov E; Nymadawa P; Wannemuehler K; Mulders MN; Hagan J; Patel MK
    Vaccine; 2020 May; 38(26):4200-4208. PubMed ID: 32381479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
    Wanlapakorn N; Puenpa J; Thongmee T; Srimuan D; Thatsanathorn T; Vongpunsawad S; Poovorawan Y
    Vaccine; 2020 May; 38(24):4016-4023. PubMed ID: 32331806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital.
    Kanamori H; Tokuda K; Ikeda S; Endo S; Ishizawa C; Hirai Y; Takahashi M; Aoyagi T; Hatta M; Gu Y; Yano H; Weber DJ; Kaku M
    Tohoku J Exp Med; 2014 Oct; 234(2):111-6. PubMed ID: 25224029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence survey of measles, rubella, varicella, and mumps antibodies in health care workers and evaluation of a vaccination program in a tertiary care hospital in Japan.
    Asari S; Deguchi M; Tahara K; Taniike M; Toyokawa M; Nishi I; Watanabe M; Iwatani Y; Makimoto K
    Am J Infect Control; 2003 May; 31(3):157-62. PubMed ID: 12734521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses.
    Nicoara C; Zäch K; Trachsel D; Germann D; Matter L
    Clin Diagn Lab Immunol; 1999 Nov; 6(6):868-71. PubMed ID: 10548578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.
    Böttiger M; Christenson B; Romanus V; Taranger J; Strandell A
    Br Med J (Clin Res Ed); 1987 Nov; 295(6608):1264-7. PubMed ID: 3120971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.
    Hayford K; Mutembo S; Carcelen A; Matakala HK; Munachoonga P; Winter A; Wanyiri JW; Searle K; Mwansa FD; Mwiche A; Phiri C; Book C; Thuma PE; Moss WJ
    Vaccine; 2019 Apr; 37(17):2387-2393. PubMed ID: 30905529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.